LITS

Company Overview — What Does MEI Pharma, Inc. Do?

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. MEI Pharma, Inc. (LITS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel P. Gold and employs approximately 100 people, headquartered in SAN DIEGO, California. With a market capitalization of $41M, LITS is one of the notable companies in the Healthcare sector.

MEI Pharma, Inc. (LITS) Stock Rating — Avoid (April 2026)

As of April 2026, MEI Pharma, Inc. receives a Avoid rating with a composite score of 22.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LITS ranks #4,089 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MEI Pharma, Inc. ranks #718 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LITS Stock Price and 52-Week Range

MEI Pharma, Inc. (LITS) currently trades at $1.17. The 52-week high for LITS is $9.00, which means the stock is currently trading -87.0% from its annual peak. The 52-week low is $0.95, putting the stock 23.0% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is LITS Overvalued or Undervalued? — Valuation Analysis

MEI Pharma, Inc. (LITS) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.50x, versus the sector average of 2.75x. The price-to-sales ratio is 684.82x, compared to 1.66x for the average Healthcare stock.

At current multiples, MEI Pharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MEI Pharma, Inc. Profitability — ROE, Margins, and Quality Score

MEI Pharma, Inc. (LITS) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -55.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -54.3% versus the sector average of -33.1%.

The operating margin is -49778.3% (sector: -66.1%). Net profit margin stands at -51331.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LITS Debt, Balance Sheet, and Financial Health

MEI Pharma, Inc. has a debt-to-equity ratio of 1.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.04x, indicating strong short-term liquidity.

LITS has a beta of 1.14, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for MEI Pharma, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MEI Pharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MEI Pharma, Inc. reported revenue of $60,000 and earnings per share (EPS) of $-0.82. Net income for the quarter was $-45M. Gross margin was 0.0%. Operating income came in at $-45M.

In Q2 2026, MEI Pharma, Inc. reported revenue of $60,000 and earnings per share (EPS) of $-0.82. Net income for the quarter was $-31M. Operating income came in at $-30M.

In Q1 2025, MEI Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.20. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q1 2026, MEI Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-4M. Operating income came in at $-4M.

Over the past 8 quarters, MEI Pharma, Inc. has experienced revenue contraction from $65M to $60,000. Investors analyzing LITS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LITS Dividend Yield and Income Analysis

MEI Pharma, Inc. (LITS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LITS Momentum and Technical Analysis Profile

MEI Pharma, Inc. (LITS) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

LITS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MEI Pharma, Inc. (LITS) ranks #718 out of 838 stocks based on the Blank Capital composite score. This places LITS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LITS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LITS vs S&P 500 (SPY) comparison to assess how MEI Pharma, Inc. stacks up against the broader market across all factor dimensions.

LITS Next Earnings Date

No upcoming earnings date has been announced for MEI Pharma, Inc. (LITS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LITS? — Investment Thesis Summary

The quantitative profile for MEI Pharma, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 16/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, MEI Pharma, Inc. (LITS) earns a Avoid rating with a composite score of 22.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LITS stock.

Related Resources for LITS Investors

Explore more research and tools: LITS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LITS head-to-head with peers: LITS vs AZN, LITS vs SLGL, LITS vs VMD.